I spent three months reviewing GLP-1 telehealth programs. One stood apart.

There are now more than two dozen telehealth companies prescribing compounded semaglutide and tirzepatide in the United States. Most of them want you to believe they are the same. Same molecules, same pharmacy networks, same provider model. After three months of comparing them, reading provider credentials, examining warranty language, sitting on intake calls, and talking to members, I can tell you they are not.

The category has a credibility problem, and it's not undeserved. The most visible programs lean hard on advertising and lean light on substance: thin physician panels, opaque pricing that climbs with each dose adjustment, customer-service teams that disappear after the first refill. A handful of services I reviewed for this report I would not personally use, even at half their price.

Eden was the outlier. Not because the marketing was slicker (it isn't), but because every claim they made held up when I pulled at it. The pharmacy network is real and licensed. The medical advisory board is composed of physicians from Albert Einstein College of Medicine, Cornell, and the University of Pittsburgh, all of whom answer their own emails. The pricing they advertise is the pricing you pay, regardless of dose. And the warranty, which most companies in this space carefully avoid offering, is unambiguous. Lose at least 10% of your body weight in six months on a plan, or get your money back.

The biology problem nobody mentions on diet apps

Most weight-loss content treats appetite as a willpower exercise. The clinical literature treats it as an endocrine one. When you restrict calories aggressively, the body responds by raising ghrelin (the hunger hormone) and lowering leptin (the satiety hormone). It's a regulatory loop honed over hundreds of thousands of years of food scarcity. That loop is what makes most diets fail at month four. It isn't a moral failing. It's a feedback system doing exactly what it evolved to do.

GLP-1 receptor agonists, the drug class that includes semaglutide and tirzepatide, work because they intervene in that loop directly. They mimic a gut hormone the body naturally produces after eating, slowing gastric emptying and signaling fullness to the brain. The clinical effect, well-documented in the STEP and SURMOUNT trials, is that patients eat less without the constant background noise of hunger that derails conventional weight loss.

The drugs are not novel. Semaglutide has been used in diabetes care since 2017. But their use for chronic weight management is recent enough that the telehealth ecosystem around them is still finding its shape. That ecosystem is where the differences between programs become consequential. The molecule is the same. What surrounds it is not.

"The molecule is just one piece. What determines outcomes is whether the patient has access to a clinician when something feels off, whether the dose is being titrated thoughtfully, and whether they have community to fall back on when the early adjustment is hard."

Dr. Halland Chen, M.D. · Chief Medical Innovation Officer, Eden · Albert Einstein College of Medicine

Inside Eden's clinical model

What Eden gets right, mechanically, is the unbundling of the patient experience. The intake is a single online form reviewed by a board-certified provider. Medication is shipped from a licensed compounding pharmacy, free and expedited, in temperature-controlled packaging. Dose adjustments are made through the patient portal without a forced upcharge. A 24/7 messaging line connects to actual clinicians, not a chatbot. I tested this at 11 PM on a Sunday and got a substantive reply within 18 minutes.

The provider panel was the part I scrutinized hardest. Telehealth has no shortage of "medical advisors" who function as marketing assets and nothing else. Eden's panel, listed publicly on their site with full credentials and institutional affiliations, is unusual in its transparency. Each member I contacted responded within 48 hours. Three of the four were willing to be interviewed for this piece on the record.

What progress looks like, in members' own words

The before-and-afters that flood the GLP-1 ad ecosystem do the category a disservice. They imply the medication is the entire story, when in practice the people who succeed are the ones who pair it with a structured program. Eden's member testimonials, all of which I was able to verify against the company's reviews on Trustpilot and Google, repeatedly mention the same three things: the absence of "food noise," consistent provider check-ins, and access to a peer community. The medication, they say, was necessary but not sufficient.

The pricing question, answered plainly

Pricing in this category is intentionally confusing. Most direct-to-consumer telehealth companies advertise a low intro figure that climbs as the dose climbs. The price you see on the landing page is rarely the price you pay at month four. Eden's pricing model breaks from this. It is fixed at the dose, regardless of titration.

For compounded semaglutide, the rate is $149 for the first month, $229 monthly thereafter. For compounded tirzepatide, $249 first month and $329 monthly. There are no membership fees, no consultation fees, no shipping fees, and no upcharges when the provider increases your dose. The weight-loss warranty is the structural commitment that makes the rest of the model work. If the program doesn't deliver a 10% loss in six months, members get their money back.†

What members are saying

My honest verdict, after three months

I went into this review prepared to be cynical. The GLP-1 telehealth space has every structural ingredient for the kind of medical-adjacent grift that has dogged the broader wellness industry for two decades: opaque pricing, unverifiable doctors, hard upselling. Several of the companies I reviewed exhibit those traits to varying degrees, and I won't be naming them here for legal reasons. You can recognize them by the way their pricing pages decline to commit to a number.

Eden is not one of those companies. The medical board is verifiable. The pharmacy network is licensed. The pricing is the pricing. The warranty is genuine. And the member outcomes (29 pounds lost on average in six months, 91% who would recommend the program) are consistent with what the GLP-1 clinical literature would predict for a well-administered program.

If you have considered GLP-1 treatment and have been waiting for a service worth recommending, this is the one I'd send my own family to. The intake takes about three minutes. There is no commitment, and the company doesn't bill anything until a licensed provider has reviewed your case and approved a plan.